https://scholars.lib.ntu.edu.tw/handle/123456789/535386
標題: | Serological responses to revaccination against HBV in HIV-positive patients born in the era of nationwide neonatal HBV vaccination | 作者: | YI-CHIA HUANG SZU-MIN HSIEH WANG-HUEI SHENG YU-SHAN HUANG KUAN-YIN LIN Chen G.-J. Yang S.-P. Liu W.-C. Su Y.-C. HSIN-YUN SUN CHIEN-CHING HUNG SHAN-CHWEN CHANG |
公開日期: | 2018 | 出版社: | Blackwell Publishing Ltd | 卷: | 38 | 期: | 11 | 起(迄)頁: | 1920-1929 | 來源出版物: | Liver International | 摘要: | Background: Serological responses to revaccination against hepatitis B virus (HBV) are unclear in HIV-positive adults who had undergone neonatal HBV vaccination and whose antibodies against HBV had waned in the era of combination antiretroviral therapy (cART). Methods: Between 2000 and 2017, 666 HIV-positive men who have sex with men (MSM) who were born after 1986, when nationwide neonatal HBV vaccination programme was implemented in Taiwan, were included for analyses. A serological response was defined when a hepatitis B surface antibody (anti-HBs) titre ?10?mIU/mL was measured 4-24?weeks after the third dose of HBV vaccination. Results: During the study period, 295 (48.7%) HIV-positive MSM (mean age, 23.2?years) who had lost HBV seroprotection were eligible for revaccination; 171 (58.0%) received at least 1 dose (20-μg) of HBV vaccine and 116 (39.3%) completed the 3-dose schedule. The serological response rate to 3 doses of HBV revaccination was 74.0% and the rate of high-titre response (anti-HBs titre ?100?mIU/mL) was 46.0%. The CD4 count before the first dose (per 50-cell/μL increment, adjusted odds ratio, 1.14; 95% confidence interval, 1.01-1.29) was positively associated with the serological response. The incident rate of HBV infection was 9.2 per 1000?person-years of follow-up among the patients who were non-responders after revaccination. Conclusions: Despite HBV vaccination in the neonatal period, the serological response rate to HBV revaccination in HIV-positive MSM was modest and could wane rapidly. Regular testing of anti-HBs should be integrated into the HIV care despite cART containing HBV-active agents. ? 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043504513&doi=10.1111%2fliv.13721&partnerID=40&md5=20d1ecf6e7f4ec10293f66fe5df990f5 https://scholars.lib.ntu.edu.tw/handle/123456789/535386 |
ISSN: | 1478-3223 | DOI: | 10.1111/liv.13721 | SDG/關鍵字: | hepatitis B core antibody; hepatitis B surface antibody; hepatitis B surface antigen; lamivudine; recombinant hepatitis B vaccine; tenofovir disoproxil; hepatitis B surface antigen; hepatitis B vaccine; virus antibody; adult; antibody titer; antiretroviral therapy; Article; CD4 lymphocyte count; cohort analysis; hepatitis B; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; major clinical study; male; men who have sex with men; observational study; retrospective study; revaccination; serology; Taiwan; treatment response; young adult; blood; complication; epidemiology; hepatitis B; Hepatitis B virus; Human immunodeficiency virus infection; immunology; male homosexuality; vaccination; Adult; Antibodies, Viral; CD4 Lymphocyte Count; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; HIV Infections; Homosexuality, Male; Humans; Male; Retrospective Studies; Taiwan; Vaccination; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。